Clinical Trial

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-04-30; most recent amendment 2026-05-11.
Status change: Not Yet Recruiting → Recruiting 2019-07-05
Trial Details
NCT Number NCT03933384
Lead Sponsor Taichung Veterans General Hospital
Conditions Hepatitis B, Viral Hepatitis
Enrollment 140 participants
Start Date 2019-08-19
Primary Completion 2027-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-14